Summary The immunohistochemical expression of c-kit proto-oncogene product in 57 breast cancer tissues was studied using anti-c-kit proto-oncogene product antibody in comparison with 20 normal breast tissues and 58 benign breast tumours. In normal breast tissues, the c-kit proto-oncogene product was strongly expressed on cell membrane and/or cytoplasm of alveolar and ductal cells. The immunoreactive score (IRS) of c-kit protooncogene product in normal mammary epithelia was 6.22 + 2.11 (mean + s.d.). In benign breast diseases, the ckit proto-oncogene product was detected heterogeneously with a reduced IRS (3.33+2.44). In breast cancer tissues, the expression of the immunoreactive c-kit proto-oncogene product was often deleted and the average IRS was significantly reduced compared to those of normal breast tissues or benign breast disease tissues. Among benign diseases, the average IRS of intraductal papilloma was significantly reduced (1.34+1.70) and the staining intensity and pattern were found to be similar to those seen in breast cancer. The results in this study suggested that the c-kit proto-oncogene product is correlated with the growth control or the differentiation of normal breast epithelium. Also, the loss of the expression of this protein may indicate the change of the signal transduction in relation to malignant transformation in human mammary epithelium.
The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor with a molecular weight of 145 000 Da, which is structurally similar to the platelet-derived growth factor receptor and the colony-stimulating factor-I receptor (Qiu et al., 1988) . Recent studies have demonstrated that the c-kit proto-oncogene product is expressed in a restricted number of human fetal, adult tissues and solid tumours (Natali et al., 1992a; Matsuda et al., 1993) .
Analysis of the tissue expression of the c-kit protooncogene in the breast tissues has shown that normal epithelium contained large amounts of c-kit-specific RNA transcripts (Natali et al., 1992b) . Immunohistochemically, homogenous expression of c-kit proto-oncogene product in normal mammary epithelia, and the loss of expression of this protein in breast cancer has been demonstrated using fresh frozen sections (Natali et al., 1992b) . However, little is known about the biological significance of this protein in benign and malignant diseases of the breast. To elucidate the relationship between the loss of this protein and the malignant transformation of human breast tissue, the immunohistochemical expression of the c-kit proto-oncogene product in malignant and non-malignant breast tissues was examined using paraffin-embedded sections on a comparative basis.
Materials and methods

Tissues
Fifty-seven patients with primary breast cancer and 58 patients with benign breast disease were studied. All patients were female and the ages of patients with breast cancer and benign disease ranged from 29 to 73 years (average age 51.8 years) and from 22-89 years (average age 43.7 years) respectively. Furthermore, normal breast tissues were obtained from 20 surgical specimens of mastectomised patients. Tissues were fixed in 10% buffered formalin and embedded in paraffin. One serial section from each tissue sample was stained with haematoxylin and eosin for routine histological examination and others were treated for demonstration of the c-kit proto-oncogene product, as described below. (Table I) .
Histopathological classification
Benign breast tissue In benign breast tissue, the expression was found to be distributed heterogeneously in the cytoplasm or on the cell membrane of tumour cells (Figure lb-d) . The average IRS of c-kit proto-oncogene product expression tended to be reduced as 3.33+2.44 in 58 benign breast diseases (Table I) (Figure 2 ). The expression was found (Table I ). The complete deletion was found in 40 of 57 (70.2%) breast cancer tissues. The IRS of c-kit protooncogene product expression in primary breast cancer was significantly lower compared to those of the normal breast tissues of the benign breast diseases (P = 0.0001) ( Table I) . To evaluate the changes of c-kit proto-oncogene product expression during malignant transformation in the human breast, the relationship between the IRS of normal duct, intraductal papilloma, non-invasive and invasive carcinoma was studied (Table III) . The IRS of intraductal papilloma was significantly lower than that of normal duct. Although (Table IV ). The patients were followed-up for three years in this study and no significant association was observed between the expression of this protein and the prognosis of patients with breast cancer.
Discussion
The immunoreactive expression of c-kit proto-oncogene product was not observed in human normal lung or seminal vesicles tissue (Natali et al., 1992a; Matsuda et al., 1993) , whereas it was found in 56% of SCLC (Matsuda et al., 1993 and 80% of seminomas (Strohmeyer et al., 1991) . On the other hand, the expression was diffusely observed in human melanocytes, but, in primary melanomas, the deletion of the c-kit protooncogene product was observed in more invasive lesions (Natali et al., 1992c) . Previously a complete inverse pattern of the expression of c-kit proto-oncogene product has also been found in the normal tissues and the malignant tumours of the breast (Natali et al., 1992a; Matsuda et al., 1993) .
In the present study the c-kit proto-oncogene product was uniformly expressed in normal breast tisses. In contrast, it was expressed heterogeneously in benign breast disease and the deletion was observed in breast cancer specimens with high incidence suggesting that the reduced c-kit protooncogene product expression is a general phenomenon in breast cancer. Previous studies have shown that direct cellcell interaction between c-kit and its ligand, the membranebound form of stem cell factor (SCF), plays an important role in signal transduction (Flanagan, et al., 1991; Reith et al., 1991) . Therefore, the high expression of the c-kit protooncogene product in normal breast tissue indicated that this protein may be related to the regulation of the proliferation and/or the differentiation of human normal mammary epithelia through the c-kit signalling pathway. Although it is possible to consider that the absence of staining in neoplastic cells is due to the presence of mutant c-kit product which is not reactive with the antibody used, the deletion of c-kit proto-oncogene product in breast cancer may indicate the changes of the signal transduction during malignancy in human mammary epithelia.
Recently, clonal analysis by means of polymerase chain reaction revealed that the intraductal papilloma was monoclonal in origin consisting of breast carcinoma, indicating that certain genetic changes had already occurred in the intraductal papilloma (Noguchi et al., 1992 (Noguchi et al., , 1994 . In the present study we found that the IRS of c-kit protooncogene product in intraductal papilloma was significantly reduced compared with that of other benign breast diseases. Since the loss of the expression of this protein could be considered to be related to the malignant transformation of human mammary epithelia (Natali et al., 1992b) , the observations in this study may indicate that the intraductal papilloma possesses higher malignant potential in benign breast diseases.
In this study no significant relationship was found between the expression of c-kit proto-oncogene product and the clinicopathological factors of breast cancer, although it is well known that the c-kit proto-oncogene product displays pleiotropic functions, such as the migration of the pigment stem cells (Keshet et al., 1991) and the proliferation of the mast cells during normal development (Wershil et al., 1992) .
The reduction of c-kit proto-oncogene product expression observed in intraductal papilloma as well as breast cancer cells suggested that the deletion of c-kit proto-oncogene product would occur in the early phase of malignant transformation of human mammary epithelia. Further investigations will be required to clarify the active mechanism of c-kit proto-oncogene product in human breast.
